Published • loading... • Updated
Traws Pharma Receives FDA Feedback on Flu Drug Development
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Traws Pharma Receives FDA Feedback on Flu Drug Development
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) announced receipt of key guidance from the U.S. Food and Drug Administration (FDA) regarding the development of its investigational antiviral, tivoxavir marboxil (TXM), for use against both bird flu and seasonal influenza. The written responses, which followed a Type B pre-Investigational New Drug (IND) meeting, provide detailed feedback on development pathways, including the use of the FDA’s Anima…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
